Incruse Ellipta (Umeclidinium) is classified as what type of medication?

Incruse Ellipta, which contains the active ingredient umeclidinium, is classified as a long-acting muscarinic antagonist (LAMA). This classification is supported by the mechanism of action of umeclidinium, which works by inhibiting the M3 muscarinic receptors in the airways, leading to bronchodilation.

LAMA medications are particularly used in the management of chronic obstructive pulmonary disease (COPD) and are sometimes employed in asthma management. They provide sustained bronchodilation over a 24-hour period with once-daily dosing, which helps patients experience improved lung function and reduced respiratory symptoms.

Understanding this classification is essential for recognizing how different classes of medications work to alleviate respiratory conditions, as well as their roles in treatment regimens. Knowledge of the specific mechanism allows healthcare providers to make informed decisions about patient care based on individual needs and characteristics of various respiratory diseases.